Literature DB >> 18632117

Effective immunosuppressant therapy with cyclophosphamide and corticosteroids in paraneoplastic cerebellar degeneration.

Jan Thöne1, Andreas Hohaus, Susanne Lamprecht, Andreas Bickel, Frank Erbguth.   

Abstract

Paraneoplastic cerebellar degeneration (PCD) is a rare immune mediated phenomenon often associated with cancer of the ovarian. Hitherto, tumor dissection is the mainstay in therapy while immunomodulatory treatment regimes often fail. Here we report on an 86 year old female patient who developed a severe pancerebellar syndrome. Clinical course, onconeural (anti-Yo) antibodies and detection of ovarian cancer suggest the assumption of PCD as the most probable diagnosis. We initiated a high-dose course of corticosteroids followed by a single dose of cyclophosphamide (600 mg/day). Surprisingly patient's condition improved and stabilized within days subsequent to cyclophosphamide application. This case demonstrates the benefit of immunosuppressive therapy in an anti-Yo positive patient with severe PCD secondary to an ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18632117     DOI: 10.1016/j.jns.2008.04.020

Source DB:  PubMed          Journal:  J Neurol Sci        ISSN: 0022-510X            Impact factor:   3.181


  13 in total

1.  Long-term efficiency of intravenously administered immunoglobulin in anti-Yo syndrome with paraneoplastic cerebellar degeneration.

Authors:  J Schessl; M Schuberth; P Reilich; P Schneiderat; N Strigl-Pill; M C Walter; B Schlotter-Weigel; B Schoser
Journal:  J Neurol       Date:  2010-12-21       Impact factor: 4.849

2.  Paraneoplastic neurological syndromes: general treatment overview.

Authors:  Aurélien Viaccoz; Jérôme Honnorat
Journal:  Curr Treat Options Neurol       Date:  2013-04       Impact factor: 3.598

3.  The role of breast MRI in the investigation of anti-Yo positive paraneoplastic cerebellar degeneration.

Authors:  Raquel Real; Ana Oliveira; Goreti Nadais; Joana Loureiro; Maria Carolina Garrett
Journal:  BMJ Case Rep       Date:  2012-03-27

4.  Early-onset immunotherapy by intravenous immunoglobulin and corticosteroids in well characterized onconeural-antibody-positive paraneoplastic neurological syndrome.

Authors:  J Honnorat
Journal:  Clin Exp Immunol       Date:  2014-12       Impact factor: 4.330

Review 5.  'Medusa head ataxia': the expanding spectrum of Purkinje cell antibodies in autoimmune cerebellar ataxia. Part 3: Anti-Yo/CDR2, anti-Nb/AP3B2, PCA-2, anti-Tr/DNER, other antibodies, diagnostic pitfalls, summary and outlook.

Authors:  S Jarius; B Wildemann
Journal:  J Neuroinflammation       Date:  2015-09-17       Impact factor: 8.322

6.  Paraneoplastic cerebellar degeneration associated with ovarian cancer.

Authors:  Alessia Erika Russo; Simona Scalone; Giulia Costanza Leonardi; Aurora Scalisi; Giorgio Giorda; Roberto Sorio
Journal:  Oncol Lett       Date:  2012-11-07       Impact factor: 2.967

7.  Response to abdominal hysterectomy with bilateral salpingo-oophorectomy in postmenopausal woman with anti-yo antibody mediated paraneoplastic cerebellar degeneration.

Authors:  Amita Bhargava; Bharat Bhushan; Gaurav M Kasundra; Khichar Shubhakaran; Guruprasad S Pujar; Basavaraj Banakar
Journal:  Ann Indian Acad Neurol       Date:  2014-07       Impact factor: 1.383

Review 8.  Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review.

Authors:  Anand Venkatraman; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2016-06-30       Impact factor: 4.511

Review 9.  Guidelines for treatment of immune-mediated cerebellar ataxias.

Authors:  Hiroshi Mitoma; Marios Hadjivassiliou; Jérôme Honnorat
Journal:  Cerebellum Ataxias       Date:  2015-11-10

10.  Dynamic Immune Cell Recruitment After Murine Pulmonary Aspergillus fumigatus Infection under Different Immunosuppressive Regimens.

Authors:  Natarajaswamy Kalleda; Jorge Amich; Berkan Arslan; Spoorthi Poreddy; Katharina Mattenheimer; Zeinab Mokhtari; Hermann Einsele; Matthias Brock; Katrin Gertrud Heinze; Andreas Beilhack
Journal:  Front Microbiol       Date:  2016-07-13       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.